ROCK inhibitors for the treatment of ocular diseases

Ramin Nourinia, Shintaro Nakao, Souska Zandi, Sare Safi, Ali Hafezi-Moghadam, Hamid Ahmadieh

研究成果: Contribution to journalReview article

6 引用 (Scopus)

抜粋

The Rho-kinase/ROCK (Rho-associated coiled-coil-containing protein kinase) pathway is involved in the pathogenesis of multiple ocular and systemic disorders. Recently, ROCK inhibitors have been suggested as novel treatments for various ocular diseases. Several in vitro, in vivo and clinical studies have demonstrated the safety and efficacy of ROCK inhibitors in the management of ocular disorders such as corneal epithelial and endothelial damage, glaucoma, retinal and choroidal neovascularisation, diabetic macular oedema and optic nerve disorders. In this review, these studies are explored with focus on the relevant clinical investigations.

元の言語英語
ジャーナルBritish Journal of Ophthalmology
102
発行部数1
DOI
出版物ステータス出版済み - 2018

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

フィンガープリント ROCK inhibitors for the treatment of ocular diseases' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Nourinia, R., Nakao, S., Zandi, S., Safi, S., Hafezi-Moghadam, A., & Ahmadieh, H. (2018). ROCK inhibitors for the treatment of ocular diseases. British Journal of Ophthalmology, 102(1). https://doi.org/10.1136/bjophthalmol-2017-310378